| Old Articles: <Older 8861-8870 Newer> |
|---|
 |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors.   |
Chemistry World
June 10, 2014
Anthony King |
Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US. |
Pharmaceutical Executive
June 9, 2014
Genenz et al. |
Surviving the Price Wars in Emerging Markets: Three Myths and Three Lessons How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment. |
Pharmaceutical Executive
June 9, 2014
Kleinrock & Noor |
Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative. |
Pharmaceutical Executive
June 9, 2014
Cliff Kalb |
The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard. |
Pharmaceutical Executive
June 9, 2014 |
Immunotherapies: The New Hope for Cancer Treatment The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey |
Pharmaceutical Executive
June 9, 2014
Getz et al. |
Adaptive Trial Design: Prepping for Adoption Biopharmaceutical companies are targeting improvements in clinical trial design as a critical factor in pipeline portfolio success. |
Pharmaceutical Executive
June 9, 2014
William Looney |
Pharma 50 Trends: Past, Present, and Future Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand. |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
Pharmaceutical Executive
June 1, 2014 |
Hopes High as EU Heads Into Leadership Change The principal drug industry associations in Europe launched a call in mid-May for "an integrated European industrial policy for the pharmaceuticals sector." |
| <Older 8861-8870 Newer> Return to current articles. |
